The ESMO presentation is a binary catalyst for October 2026. The stand-alone efficacy data will be critical for partnership discussions. Given the stock's poor historical reaction to prior neutral reports, traders should wait for the actual data release before positioning. Monitor for any pre-ESMO abstract or partnership announcement.
Price Chart
Executive Summary
Evaxion will present three-year Phase 2 data for personalized cancer vaccine EVX-01 at ESMO 2026 (Oct 23-27). The third-year data includes a stand-alone therapy cohort, offering insight into EVX-01's effect without anti-PD-1 combination. Prior two-year data showed a 75% ORR and durable responses, but the stock has historically declined on prior neutral reports, suggesting limited market enthusiasm for early-stage data milestones.
Key Facts
- Three-year Phase 2 data for EVX-01 will be presented at ESMO Congress 2026 (Oct 23-27, Madrid).
- Third-year data includes a subset of patients receiving EVX-01 as stand-alone therapy (no anti-PD-1 combination).
- Prior two-year data showed 75% ORR (12/16 patients), 92% durable response at 2 years, and no relapses.
- EVX-01 induced immune response in all patients; 86% of targeted neoantigens generated T-cell responses.
- Market cap is ~$26M; historical reports on EVAX have averaged -11.81% T+20 returns with 0% win rate.
Financial Impact
No financial data provided; clinical-stage company with no revenue.
Risk Factors
- Three-year data may not show incremental benefit over two-year data.
- Stand-alone therapy cohort may have limited sample size, reducing statistical significance.
- Historical reports on EVAX have consistently underperformed, suggesting market skepticism.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3329028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.56%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.88%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.13%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.13%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.56%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.89%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.89%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.39%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.39%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access